Quarterly report [Sections 13 or 15(d)]

EQUITY

v3.25.3
EQUITY
 9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Equity EQUITY
Accumulated Other Comprehensive Income (Loss)
The following table presents changes in the components of AOCI, net of taxes, for the nine months ended September 30, 2025:
Cash Flow Hedge Cumulative Foreign Currency Translation Adjustments Total
(in thousands)
Balance at December 31, 2024 $ 21,518  $ (356,630) $ (335,112)
Other comprehensive income (loss) before reclassifications
 (826) 187,410  186,584 
Amount reclassified from AOCI (10,363) —  (10,363)
Net other comprehensive income (loss) (11,189) 187,410  176,221 
Balance at September 30, 2025 $ 10,329  $ (169,220) $ (158,891)
Earnings Per Share
Basic net income per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding during the period. The calculation of diluted net income per common share includes the effects of the assumed exercise of any outstanding stock options, the assumed vesting of shares of restricted and deferred stock awards and the assumed conversion of our convertible senior notes, where dilutive.
The following table sets forth the computation of weighted average common shares outstanding:
Three Months Ended
September 30,		 Nine Months Ended
September 30,
2025 2024 2025 2024
Weighted average common shares—basic 232,043,356  230,374,307  231,706,216  229,923,989 
Effect of dilutive securities:
    Stock options and restricted stock 2,708,976  1,941,001  2,891,759  2,226,003 
    Convertible senior notes —  13,004,660  127,830  3,778,760 
Weighted average common shares—diluted 234,752,332  245,319,968  234,725,805  235,928,752 
The following table shows securities excluded from the calculation of diluted net income per common share because such securities are anti-dilutive:
Three Months Ended
September 30,		 Nine Months Ended
September 30,
2025 2024 2025 2024
Options to purchase shares of common stock —  —  —  3,750 
Restricted stock and deferred stock—unvested 549,099  2,147,167  549,539  2,162,662 
Conversion shares related to the convertible senior notes 14,946,450  —  14,946,450  9,225,900 
Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding 15,495,549  2,147,167  15,495,989  11,392,312 
Transactions with Noncontrolling and Redeemable Noncontrolling Interest Partners
During the nine months ended September 30, 2025, we paid $122.3 million to purchase a portion of the noncontrolling interest in certain subsidiaries in Europe. We also acquired an additional 24% interest in OCESA from CIE, which resulted in a decrease of $746.1 million in redeemable noncontrolling interest.